Lundbeck to acquire Alder BioPharmaceuticals in transaction valued at $1.95 billion
H. Lundbeck and Alder BioPharma announced an agreement for Lundbeck to acquire Alder. Lundbeck will commence a tender offer for all outstanding shares of Alder at 18.00 per share in cash, along with one non-tradeable CVR that entitles them to an additional 2.00 per share. September 16, 2019